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Protocol
AbstrACt
Introduction Vitiligo is a condition resulting in white 
patches on the skin. People with vitiligo can suffer 
from low self-esteem, psychological disturbance 
and diminished quality of life. Vitiligo is often poorly 
managed, partly due to lack of high-quality evidence 
to inform clinical care. We describe here a large, 
independent, randomised controlled trial (RCT) assessing 
the comparative effectiveness of potent topical 
corticosteroid, home-based hand-held narrowband 
ultraviolet B-light (NB-UVB) or combination of the two, 
for the management of vitiligo.
Methods and analysis The HI-Light Vitiligo Trial is 
a multicentre, three-arm, parallel group, pragmatic, 
placebo-controlled RCT. 516 adults and children with 
actively spreading, but limited, vitiligo are randomised 
(1:1:1) to one of three groups: mometasone furoate 
0.1% ointment plus dummy NB-UVB light, vehicle 
ointment plus NB-UVB light or mometasone furoate 
0.1% ointment plus NB-UVB light. Treatment of up to 
three patches of vitiligo is continued for up to 9 months 
with clinic visits at baseline, 3, 6 and 9 months and four 
post-treatment questionnaires. The HI-Light Vitiligo Trial 
assesses outcomes included in the vitiligo core outcome 
set and places emphasis on participants’ views of 
treatment success. The primary outcome is proportion of 
participants achieving treatment success (patient-rated 
Vitiligo Noticeability Scale) for a target patch of vitiligo at 
9 months with further independent blinded assessment 
using digital images of the target lesion before and after 
treatment. Secondary outcomes include time to onset of 
treatment response, treatment success by body region, 
percentage repigmentation, quality of life, time-burden 
of treatment, maintenance of response, safety and 
within-trial cost-effectiveness.
Ethics and dissemination Approvals were granted by 
East Midlands—Derby Research Ethics Committee (14/
EM/1173) and the MHRA (EudraCT 2014-003473-42). The 
trial was registered 8 January 2015 ISRCTN (17160087). 
Results will be published in full as open access in the NIHR 
Journal library and elsewhere.
trial registration number ISRCTN17160087.
IntroduCtIon  
Vitiligo is a chronic progressive condition 
causing loss of skin pigmentation. It affects 
around 0.5%–1% of the world’s population, 
and can develop at any age, although onset 
between the age of 10 and 30 years is most 
common.1–4 Vitiligo can have a major impact 
on the quality of life of affected people,5 who 
often experience psychological problems 
such as shame, depression and anxiety, low 
self-esteem and social isolation.6 7
Current clinical guidelines for the manage-
ment of vitiligo recommend narrowband 
ultraviolet-B light (NB-UVB), topical cortico-
steroids, topical tacrolimus and combination 
therapies.8 9 However, the evidence base for 
treatments is currently limited.10 11
A Cochrane systematic review assessing 
interventions for vitiligo was updated in 
strengths and limitations of this study
 ► Answers research questions prioritised by people 
with vitiligo and healthcare professionals as a part 
of a James Lind Alliance Priority Setting Partnership.
 ► Appropriately powered, pragmatic, randomised con-
trolled trial, which may influence clinical decision 
making for a condition with little high-quality evi-
dence to support treatment options.
 ► Trial places emphasis on patient-reported outcomes 
and includes the core outcome set for vitiligo.
 ► Blinding of treatment allocation may be compro-
mised due to observable side effects (eg, erythema 
and tanning of the surrounding skin), particularly for 
those receiving active light therapy.
 ► Primary outcome is based on participant-reported 
treatment success at 9 months (Vitiligo Noticeability 
Scale), further improvement may occur after this 
time as residual hyperpigmentation resolves.
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2015.12 This review identified 96 randomised controlled 
trials (RCTs) of vitiligo treatments, involving 4512 partic-
ipants. Despite this large number of trials, the quality of 
the included studies was generally poor, making it diffi-
cult to make firm recommendations for vitiligo treat-
ment. The majority of the studies included fewer than 
50 participants, were at high or unclear risk of bias and 
few involved children. Nevertheless, the Cochrane review 
identified some evidence in support of NB-UVB, and the 
combination of NB-UVB with other active interventions 
(eg, topical corticosteroids or calcineurin inhibitors) 
appeared to be more effective than monotherapy. A 2016 
review of the use of NB-UVB for the treatment of vitiligo13 
also concluded that guidance on dosing and administra-
tion of NB-UVB requires further study.
There is some evidence to suggest that starting vitiligo 
treatment when lesions first appear is likely to result in 
better treatment response, when vitiligo patches are 
actively changing and some melanin is still present.14 
However, current practice is to reserve NB-UVB treat-
ment for patients with widespread and established 
vitiligo,8 as the treatment requires thrice weekly visits to 
the hospital for full body light therapy. The recent avail-
ability of hand-held NB-UVB units for private purchase 
on the open market means that early intervention using 
treatment at home is now a possibility. Benefits of home-
based treatment, if shown to be safe and effective, would 
be a reduction in time and financial burden for patients 
and hospital services, and reduced exposure of healthy 
skin to NB-UVB light as treatment can be targeted more 
effectively. Our small pilot RCT, involving 29 participants, 
compared hand-held NB-UVB with dummy devices for 
the management of vitiligo.15 This pilot demonstrated 
that people with vitiligo were keen to use home-based 
light therapy, and that the devices were safe and well 
tolerated when used in a domestic setting.
A James Lind Alliance Priority Setting Partnership iden-
tified a ‘top 10’ list of priority areas for vitiligo research 
that are important to people with vitiligo and health-
care professionals responsible for their care.16 Two of 
these prioritised areas relate to the use of light therapy 
for the management of vitiligo: ‘Which treatment is 
more effective for vitiligo: steroid creams/ointments or 
light therapy?’ and ‘How effective is UVB therapy when 
combined with creams or ointments in treating vitiligo?’ 
The prioritisation work was shared with the NIHR Health 
Technology Assessment Programme who subsequently 
invited applications to address these two priority topics in 
open competition. The contract to conduct the commis-
sioning brief was awarded to this team.
objectives
Primary objective:
1. To evaluate the comparative safety and effectiveness 
of home-based interventions (potent topical cortico-
steroids and hand-held NB-UVB light) for the man-
agement of early and limited vitiligo in adults and 
children. Specifically, we are comparing:
a. Potent topical corticosteroid (mometasone furo-
ate 0.1% ointment) with hand-held NB-UVB light;
b. Potent topical corticosteroid (mometasone furo-
ate 0.1% ointment) with combination of hand-
held NB-UVB light and potent topical corticoste-
roid.
Secondary objectives:
1. To assess whether treatment response (if any) is main-
tained once the intervention is stopped.
2. To compare the cost-effectiveness of the interventions 
from a National Health Service (NHS) and a family 
perspective.
MEthods
The analysis and reporting of the trial will be in accor-
dance with Consolidated Standards of Reporting Trials 
guidelines.17
study design and setting
The trial is a multicentre three-arm, parallel group, 
pragmatic, placebo-controlled RCT, recruiting adults 
and children with early and limited vitiligo. The trial 
treatments are home-based therapies (potent topical 
corticosteroid and hand-held NB-UVB), and their use 
is prescribed and overseen in a secondary care setting 
across 18 hospitals in the UK. A full list of recruiting 
centres can be found in the 'Acknowledgements' 
section. A mixed-methods process evaluation is being 
conducted alongside the HI-Light Vitiligo Trial. The 
full protocol is available at www. vitiligostudy. org. uk.
Participants
Eligibility
Inclusion criteria
Participants aged 5 years and over with a diagnosis of 
non-segmental vitiligo, limited to approximately 10% 
or less of body surface area, and at least one vitiligo 
patch that has been active in the last 12 months 
(reported by the participant, or parent). Participants 
should be willing to stop any other active therapies 
for their vitiligo at time of randomisation, be able to 
administer the trial treatments safely at home (able to 
follow the treatment instructions and children able to 
comply with the necessary safety precautions). Partici-
pants also need to be willing and able to give informed 
consent (or parental/guardian consent in the case of 
children).
Exclusion criteria
Potential participants with segmental or universal 
vitiligo, vitiligo limited to areas contraindicated for 
treatment with potent topical corticosteroid (eg, 
around the genitals) or evidence of marked Koebner 
phenomenon (lesions appearing in sites of skin 
trauma) as such potential participants are likely to 
require urgent care. Also excluded are potential 
participants with a history of skin cancer, radiotherapy 
use or photosensitivity; women who are pregnant, 
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breastfeeding or likely to become pregnant during 
the 9-month treatment period; those currently using 
immunosuppressive drugs, or involved in another clin-
ical trial and those with allergy or contraindication to 
mometasone furoate or any of its excipients. Poten-
tial participants are not randomised into the trial if 
the research nurse or investigator feels that they are 
unable to follow the treatment instructions, or if chil-
dren are unable to comply with the necessary safety 
precautions.
Participant timeline
Participants are enrolled in the trial for a total of up to 
21 months (9 months treatment phase, up to 12 months 
follow-up). During the treatment phase, participants 
attend a hospital clinic five times (two consecutive days 
at baseline for recruitment, medical photography, photo-
sensitivity assessment (minimum erythema dose (MED) 
test) and training in use of the interventions), followed 
by assessment at 3, 6 and 9 months for compliance 
and outcome. The additional follow-up is by 3-monthly 
Figure 1 Flow of participants through the trial. MED, minimum erythema dose.
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questionnaires, self-completed by post or email link. 
Due to trial timelines, participants recruited towards the 
end of the recruitment may be followed-up for a shorter 
period of time.
Flow of participants through the trial is summarised in 
figure 1, and details of the data collection schedule are 
summarised in table 1.
Recruitment
Potential participants are identified through secondary 
care dermatology and paediatric clinics, through mail-
shots from general practices and by self-referral as a result 
of community advertising and trial publicity. Potential 
participants are initially screened by telephone in order 
to ensure that only people who are potentially eligible to 
take part are invited to attend a clinic appointment.
randomisation and blinding
Participants are randomised to one of three treatment 
groups in a ratio of 1:1:1 as follows:
 ► Topical corticosteroid ointment plus dummy NB-UVB 
light (corticosteroid only);
 ► Vehicle ointment plus NB-UVB light (light therapy 
only);
 ► Topical corticosteroid ointment plus NB-UVB light 
(combination therapy).
Randomised allocation to treatment groups is mini-
mised by recruiting centre, body region of target patch 
(face and neck, hands and feet or rest of the body) and 
age (5–16 years or >16 years), weighted towards mini-
mising the imbalance in trial arms with a probability of 
0.8. After all eligibility criteria have been confirmed and 
medical photographs taken, participants are randomised 
by staff at the recruiting hospital via a secure web server 
created and maintained by the Nottingham Clinical Trials 
Unit.
Participants are only randomised into the trial once 
they have completed the training in use of the trial inter-
ventions, the results of the MED test are known and the 
participant has attended medical photography for their 
baseline digital photograph.
Participants, research nurses, principal investigators, 
members of trial management group and data analysts 
are blinded to treatment allocation. Only the Nottingham 
Clinical Trials Unit (NCTU) programmer, the medical 
physics staff, pharmacy staff and the NCTU Quality Assur-
ance staff have access to the treatment allocation schedule 
for the sole use of preparing, blinding and checking of 
the trial treatments.
While every effort is made to maintain blinding of 
the trial interventions, there is a risk that participants 
may be able to guess their treatment allocation as a 
result of side effects of the interventions (eg, redness 
and tanning of the skin). To minimise detection bias, 
outcomes will be assessed by blinded assessors (both 
independent clinicians and a panel of patients), using 
digital images taken at baseline and at 9 months. 
Participant information leaflets will emphasise that all 
participants will receive at least one active treatment for 
their vitiligo, thus reducing potential unblinding due to 
lack of treatment response. During our previous trial in 
which participants were randomised to active or dummy 
light therapy devices, 70% (19/27) of participants and 
40% (16/27) of research nurses, guessed treatment allo-
cation correctly. The main reasons for unblinding of the 
research nurses were redness of the skin (30% (3/10)) 
and improvement in vitiligo (60% (6/10)) in the active 
group, and lack of treatment response (100% (6/6)) in 
the placebo group.
Interventions
Topical therapy: potent topical corticosteroid
Mometasone furoate 0.1% ointment (Elocon, Merck, 
Sharp and Dohme, PL00025/0578), a potent corticoste-
roid used once daily, has been recommended in the Euro-
pean Clinical Guidelines for the management of vitiligo.9 
In order to minimise the risk of adverse reactions, the 
Guidelines recommend a discontinuous regimen involving 
periods of use followed by break periods. Possible adverse 
reactions to mometasone furoate 0.1% (as listed in the 
Summary of Product Characteristics18) include: infec-
tion, folliculitis, paraesthesia, burning sensation, contact 
dermatitis, skin hypopigmentation, hypertrichosis, skin 
striae, acneiform dermatitis, skin atrophy, pruritus, appli-
cation site pain and visual disturbance. Participants are 
advised to stop treatment with the ointment if they notice 
any side effects and to contact the local research team for 
review and advice on when to restart treatment.
Topical therapy: vehicle ointment
The vehicle ointment is an inert ointment (white soft 
paraffin) present in the base of mometasone furoate oint-
ment. It is relatively free of side effects.19
Topical therapy: treatment regimen
To minimise the risk of adverse reactions, topical therapy 
is to be applied as a thin layer to the affected patches 
once daily on alternate weeks (1 week on, 1 week off), 
for a period of 9 months. Participants are instructed that 
topical therapy should be applied at least 2 hours after the 
hand-held light device is used in order to avoid interac-
tion of the NB-UVB light and topical corticosteroid.
Participants are initially supplied with two x 90 g tubes 
of ointment after randomisation. Additional tubes are 
prescribed by the investigator as required.
Light therapy: NB-UVB device
Several brands of hand-held NB-UVB units are CE marked 
for use in treating vitiligo and suitable for use at home. 
Dermfix 1000 MX units are being used for this trial.
Known adverse reactions to NB-UVB light include: 
erythema, blistering, burns, pruritus, perilesional hyper-
pigmentation, hypersensitivity reactions, cold sores and 
dry skin. Potential long-term risks include skin ageing and 
increased risk of skin cancer. Side effects can be reduced 
by appropriate use of the device.
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Light therapy: dummy device
The dummy light therapy device is identical to the active 
device, with the exception that a specially designed spacer 
comb, identical to that found on the active device, is used 
to block the transmission of NB-UVB light to the skin. 
Active and dummy devices are tracked using manufactur-
er’s serial numbers. Experience from our pilot trial15 has 
shown that the use of a dummy device is acceptable to 
patients and is effective in blocking the UVB radiation.
There are no known side effects of the dummy NB-UVB 
devices.
Light therapy: quality control prior to distribution
All light therapy devices are tested for safety and output by 
the Medical Physics Department at Nottingham Univer-
sity Hospital NHS Trust before sending to participants. If 
an active device is found to have an output that is ±10% 
of the expected mean output, or if a dummy device tests 
positive for any NB-UVB emission, the device is returned 
to the manufacturer. Any device which is damaged or 
ceases to function during the treatment phase is replaced 
with a new unit.
Light therapy: regimen
Although NB-UVB (UV radiation wavelengths of 311–312 
nanometres) is now the most common form of light 
therapy used to treat skin conditions, many gaps remain in 
knowledge about its use. In a 2016 paper,13 Madigan et al 
published a list of 12 key questions regarding the use of 
narrowband UVB for generalised vitiligo. How each of 
these questions has been addressed within the context of 
the HI-Light trial is presented in table 2. Prior to rando-
misation, all participants receive an MED test, to ensure 
eligibility for the trial. Results of the MED test are not 
used to determine starting dose of the light therapy, but 
instead to ensure that the participant does not have any 
undiagnosed photosensitivity disorder. All participants 
follow a predefined treatment schedule for the light treat-
ment, with a starting dose of 0.05 J/cm2 (see supplemen-
tary  appendix 1).
Treatment is self-administered at home, every other 
day, for a period of 9 months. If the vitiligo is on the face, 
or in an area that is inaccessible, participants are advised 
to seek help from someone else to administer the treat-
ment. Parents/guardians are instructed in how to admin-
ister the treatment for their child.
The exposure time for each session is increased incre-
mentally. Participants are asked to keep a record of their 
treatments in a treatment diary. Details are provided to 
participants on how to progress through the treatment 
schedule, step down or temporarily stop, depending on 
treatment response (a summary of instructions can be 
found in online supplementary appendix 2). Full instruc-
tions from the participants’ handbook can be found at 
www. vitiligostudy. org. uk. All devices are supplied with 
gloves and UV protective goggles (for both the partici-
pants and their helper as required), which must be worn 
at all times during use.
Storage and distribution of trial treatments
A central pharmacy and distribution centre (Mawds-
leys, Doncaster, UK) receives blinded interventions. On 
randomisation of a participant by the trial investigator/
nurse, the pharmacy is notified of the container numbers 
of ointment and the device to be allocated to that partic-
ipant via a web-based system. Trial treatments are then 
sent directly to the participant’s home following check 
and release by a qualified person.
Training in use of interventions
Before randomisation, all participants receive training 
in how to apply the ointment, including guidance on 
avoiding application to the eyelids and sensitive body sites 
such as the genital area. In addition, participants receive 
training in the correct use of the light therapy devices. 
A specially developed online training video is available 
(www. vitiligostudy. org. uk) and face-to-face training with 
the research nurse or investigator is given, covering 
how to record treatments, manage side effects and use 
of the treatment schedule. Written instructions are also 
provided for the participants to take home. Training 
takes place prior to randomisation and participants have 
the opportunity to ask questions and points of clarifica-
tion. Anyone considered unable to follow the treatment 
regimen is excluded from the trial. Two weeks after rando-
misation, participants are telephoned by the trial team to 
check how they are getting on with the interventions and 
to confirm their understanding of treatment usage and 
completion of the treatment diaries. Additional training 
on use of either treatment is provided to the participants 
at this time point (over the telephone or face-to-face), if 
needed.
Choice of vitiligo patches for treatment
During the baseline clinic appointment, participants 
are asked to select up to three patches of vitiligo for 
treatment; one for each of three anatomical regions 
(head and neck, hands and feet and rest of body). 
One of these three patches is selected by the partic-
ipants as being the patch that they would most like 
to see an improvement in. This will be used as the 
target patch for the primary outcome assessment. 
Vitiligo is known to respond differently at different 
body sites, with the face and neck being more likely 
 to respond to treatment than the hands and feet.20 
Training material provided to sites advised nurses to 
inform participants that patches on the hands and feet 
may be more difficult to treat so they may wish to choose 
a target patch from one of the other body regions.
If participants wish to treat additional patches of 
vitiligo they are free to do so, but the additional patches 
are not assessed as part of the trial. Participants are 
encouraged to consider the additional time burden of 
treating more than three patches, and to prioritise treat-
ment of the study patches if the time burden becomes 
restrictive.
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Adherence
Adherence is recorded in a treatment diary, which acts as 
an aide memoire to inform clinic appointment questions 
about the number of light treatment sessions and oint-
ment applications undertaken since the last clinic visit. 
Collection of these data at each clinic visit (every 3 months) 
Table 2 Key questions regarding the use of NB-UVB for generalised vitiligo13
Question Strategy tested in the HI-Light Vitiligo Trial
1 What is the optimal weekly frequency 
of NB-UVB treatment?
HI-Light Trial: every other day (3–4 times weekly).
Rationale: this is the most commonly used treatment regimen in the UK.
2 With regard to initial dosing, which 
strategy should ideally be employed?
HI-Light Trial: all participants started on the same low dose, 0.05 J/cm2.
Rationale: MED test was carried out before treatment, but only to identify any 
undiagnosed cases of photosensitivity. Starting at a fixed low dose to minimise the risk of 
symptomatic erythema was felt to be safer for home delivery of NB-UVB.
3 At subsequent treatments, what 
increments should be used for 
dose escalation in the absence of 
perceptible erythema?
HI-Light Trial: 10% dosing increase after each treatment not followed by erythema.
Rationale: this reflects typical clinical practice in UK phototherapy services
4 What is the maximum acceptable 
dose to be given in a single 
treatment?
HI-Light Trial: maximum dose in the trial is 2.81 J/cm2.
Rationale: this reflects typical clinical practice in UK phototherapy services.
5 What is the ideal practice for dose 
adjustment following symptomatic 
erythema?
HI-Light Trial: patient self-adjustment for grades 1 and 2 erythema (according to flow chart 
in patient handbook) and investigator adjusted dosing for grades 3 and 4.
Rationale: the upwards and downwards dosing used in the trial reflects the clinical 
practice of most UK phototherapy services.
6 How should the protocol be adjusted 
for missed doses?
HI-Light Trial: varies in function of number of missed treatments. 1 or 2 missed: go back 
one step on treatment schedule; 3 missed: go back two steps on treatment schedule; 
4–6 missed: 50% of last dose; 6+ missed restart treatment schedule from beginning.
Rationale: this conservative approach ensures that participants who have missed a lot of 
doses are not at risk of symptomatic erythema when they restart treatment.
7 How should a ‘course’ of NB-UVB 
therapy be defined? (ie, At what 
interval should further exposure be 
reassessed?)
Not directly applicable within the scope of the trial.
8 What is the maximum number of 
exposures allowable for patients 
with vitiligo given the potential risk of 
carcinogenesis with NB-UVB?
Not directly applicable within the scope of the trial. Participants in the trial will only be 
treating limited areas of skin and the total number of treatments will be less than the 
current maximum recommended number of treatments.
9 Should dosing strategies differ when 
treating children with vitiligo?
HI-Light Trial: children are treated in the same way as adults. Parents are given the choice 
of what patches they are comfortable treating, and may opt out of treating sensitive areas 
if they wish to do so.
Rationale: the home-based treatment is more flexible than hospital-based full-body 
treatment, so it is possible for children to be treated in the same way as adults.
10 Should shielding of sensitive 
structures (eyelids, areolas and 
genitals) be a universal requirement, 
or is it safe to expose these areas if 
affected by vitiligo?
HI-Light Trial: the trial excludes treatment of vitiligo in the genital region. Other sensitive 
areas can be treated if they are affected by vitiligo, but will not otherwise be exposed to 
NB-UVB due to the localised nature of treatment using a hand-held device. If treating the 
eyes, patients are advised to seek assistance from someone else so that they can keep 
their eyes closed during treatment, thus reducing the risk of accidental exposure during 
treatment.
11 What is the most accurate definition 
of treatment unresponsiveness?
HI-Light Trial: treatment response is assessed in terms of its onset; unresponsiveness 
would be defined by patient report of 'stayed the same' or 'got worse' in response to 
the question, ‘Compared with the start of the study, has there been a change in the 
vitiligo patch?' Participants are encouraged to continue treatment for as long as they are 
happy to do so. The trial may provide useful data on when and how to define treatment 
unresponsiveness.
12 How frequently should patients with 
vitiligo undergo surveillance following 
completion of a NB-UVB treatment 
protocol for both signs of relapse 
and adverse events? Is there a role 
for phototherapy in maintenance 
following repigmentation?
HI-Light Trial: long-term treatment response is being assessed 3-monthly for 1 year 
following completion of NB-UVB treatment. The trial has not been designed to evaluate 
the use of intermittent treatment for maintenance of response.
Rationale: patients are particularly interested in how long treatment response might last 
and this is now a core outcome domain for vitiligo clinical trials.
MED, minimum erythema dose; NB-UVB, narrowband ultraviolet B-light
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also helps the nurse to check participants’ understanding 
of treatment and to encourage adherence; additional 
training is provided at the clinic visit if it has been noticed 
the participant is not using the device appropriately or 
has misunderstood the treatment schedule.
Concomitant medications
Some medications can occasionally cause photosensitivity 
(a rash in areas of skin exposed to light), although the 
risk of these reactions is low for NB-UVB light. As such, 
no changes to existing medications are required at the 
onset of the trial.
At the end of the 9-month treatment phase, participants 
return their device and any unused ointment to the trial 
team and are asked not to use any active treatments for 
their vitiligo during the follow-up period (if possible), so 
that the duration of any observed treatment effect can be 
evaluated. If participants do start active vitiligo therapy, 
this is recorded in the 3-monthly questionnaires.
Treatment modification following adverse events
Participants are instructed to record adverse events in 
their treatment diaries and to contact their recruiting 
centre if they experience side effects of concern, or a 
serious adverse event (whether related to the trial treat-
ment or not). For treatment-related side effects, or 
drug-induced photosensitivity, the site research team 
provide telephone advice or arrange for a dermatology 
consultation, as necessary. Treatment modifications, 
including reduction or suspension (temporary or perma-
nent) of either topical corticosteroid or light therapy use 
is at the discretion of the trial nurse or dermatologist, as 
appropriate.
In case of a medical emergency where an active treat-
ment of the ointment or the device would need to be 
stopped, active treatment of both interventions should 
be assumed. If knowledge of a participant’s allocation 
is necessary, the local investigator can access an online 
blind-break system held by NCTU, which is available 
24 hours a day.
outcomes
Previous research has demonstrated a discrepancy 
between what is collected in vitiligo trials and the 
outcomes that patients feel are most important to them.21 
An international e-Delphi consensus exercise22 estab-
lished core outcome domains for vitiligo trials, including: 
repigmentation, cosmetic acceptability of treatment 
response, maintenance of gained repigmentation, cessa-
tion of spread, quality of life, burden of treatment and 
safety. The HI-Light Vitiligo Trial will assess all of these 
core outcome domains.
Primary outcome
The primary outcome of treatment success will be assessed 
at 9 months for a target patch of vitiligo for each partic-
ipant: defined as the patch that the participant would 
most like to see an improvement in. Treatment success 
is defined as a participant’s report that their vitiligo is 
either ‘a lot less noticeable’ or ‘no longer noticeable’ in 
response to the question: ‘Compared with the start of the 
study, how noticeable is the vitiligo now?' using the vali-
dated Vitiligo Noticeability Scale (VNS).23 Participants 
are shown a digital image of their vitiligo at baseline to 
inform this judgement at 9 months. Preliminary valida-
tion of the VNS has shown it to have good face validity 
with patients and good construct validity, acceptability 
and interpretability.23
Digital images of the target patch (taken at baseline 
and 9 months) will be assessed by a panel of independent 
assessors comprising three patients with vitiligo, thus 
providing blinded assessment of the primary outcome 
to explore the impact of detection bias, due to potential 
unblinding of the trial participants, in sensitivity analysis.
Secondary outcomes during treatment phase
a. Onset of treatment response: assessed by participant and 
investigator for each patch of vitiligo in each of the 
three body regions. The question ‘Compared with 
the start of the study, has there been a change in the 
vitiligo patch?’ is asked at 3, 6 and 9 months, with 
the patient and investigator responding with one of 
the following: stayed the same, improved, got worse.
b. Percentage repigmentation: recorded by investigators at 
3, 6 and 9 months clinic visits for each of the assessed 
patches. In addition, an independent dermatologist 
will provide blinded assessment based on photos of 
the target patch at baseline and 9 months.
c. Pattern of repigmentation (perifollicular, marginal, 
diffuse, mixed, hyperpigmentation) will be recorded 
for descriptive purposes.
d. Quality of life: assessed at three time points: baseline, 
end of treatment (9 months) and end of follow-up 
(21 months). VitiQOL (vitiligo-specific), Skindex 
29 (dermatology-specific) and EQ-5D-5L (gener-
ic health-related quality of life) are completed by 
adults aged 18 years and above.24–28 All children up 
to and including 17 years of age at randomisation 
will complete the CHU 9D (children’s health-relat-
ed quality of life), and children aged 11 years and 
above at randomisation will complete the EQ-5D-5L 
(generic health-related quality of life).28–31
e. Time burden of treatment: participant-reported treat-
ment burden at 3, 6 and 9 months based on aver-
age duration and number of treatment sessions and 
adherence with the treatment schedule. To be pre-
sented for light therapy and topical corticosteroid 
therapy separately.
Secondary outcome during treatment and follow-up phase
a. Participant-reported treatment success, analysed by body re-
gion: using the VNS, assessed for each patch at 3, 6 
and 9 months, and again in follow-up questionnaires 
at 12, 15, 18 and 21 months, to assess long-term pa-
tient-reported noticeability for each body region.
b. Resource use to inform within-trial cost-effectiveness 
analysis from an NHS perspective (primary) and a 
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family perspective (secondary). Participant self-report 
of healthcare appointments (number, which profes-
sional, and if related to vitiligo), prescriptions and 
personal expenses, in relation to vitiligo over the 
course of the treatment and follow-up phases.
Secondary outcome during follow-up phase only
Maintenance of treatment response: assessed by participants 
for each patch of vitiligo in each of the three body 
regions during the long-term follow-up period (12, 15, 
18 and 21 months questionnaires). The question asked is 
“Thinking now about since you stopped using the study 
treatments, has the vitiligo on your [Head and Neck, Hands 
and Feet, Rest of Body] patch: stayed the same, improved, 
got worse?” Since this response is a subjective personal 
assessment of how the treatment response is perceived, 
participants are not shown their end of treatment photo-
graph when making this judgement.
Safety outcomes
The safety end points are proportion of adverse device 
effects and adverse reactions to the topical corticosteroid 
and NB-UVB during the treatment phase.
Adverse events are recorded in the trial database, and 
monitored by the trial coordinating centre and relevant 
oversight committees. Erythema (redness) of grade 1 or 
2 is not considered an adverse event as this is an expected 
treatment response from use of NB-UVB. All serious 
adverse events (SAEs) are reported directly to the trial 
coordinating centre and assessed for seriousness, expect-
edness and causality by the Chief Investigator, or dele-
gated medical monitor. SAEs are recorded and reported 
to the Medicines Health Regulatory Authority (MHRA) 
and Research Ethics Committee (REC) as part of the 
annual reports. Serious unsuspected serious adverse reac-
tion (SUSARs) will be reported within the statutory time-
frames to the MHRA and REC.
data, monitoring and analysis
Data collection and management
Data collection and skin assessments are undertaken by 
trained staff at the recruiting hospitals. Participants who 
do not attend clinic visits at 3 or 6 months continue to be 
invited to subsequent follow-up visits unless they decline 
further participation in the trial. Every effort is made to 
ensure the 9-month follow-up visit takes place, and if a 
face-to-face visit cannot be arranged, data are collected 
via telephone or email if possible. Data captured at clinic 
visits are entered by site staff into the web-based trial 
database.
The year-long follow-up after treatment is by self-com-
pleted questionnaires, either via an email link to the trial 
online system or by post, sent with a stamped addressed 
envelope. Reminders are sent (via email or post) if the 
questionnaire remains uncompleted after 2 weeks, and 
again after 3 weeks. The trial coordinating centre also 
then chases up outstanding questionnaires after 3 weeks 
via telephone.
Detailed data management processes and central and 
on-site monitoring procedures are documented in a data 
management plan. All sites are monitored at least once 
after the first five randomisations from that site, and trig-
gered monitoring visits are undertaken if any concerns 
about the site are raised. Database validation checks are 
conducted centrally including checks for missing data, 
out of range values, illogical entries and invalid responses. 
Data entered by sites into the trial database are subject to 
monitoring and review by coordinating centre staff, and 
data queries are raised as necessary. All receive at least 
one site monitoring visit during the trial.
Trial management
Management of the trial is the responsibility of the Trial 
Management Group, which meets regularly, usually 
monthly, throughout the trial. Data collection, adherence 
and retention rates are monitored by this group. Trial 
oversight is by the independent Trial Steering Committee. 
Unblinded trial data are monitored in confidence by the 
independent Data Monitoring Committee, which reports 
to the Trial Steering Committee. Both oversight commit-
tees meet at least annually. The composition of both over-
sight committees and their charters can be found on the 
trial website.
Sample size
Our choice of minimum clinically important difference 
between the groups has been informed by a survey of 
the clinical membership of the UK Dermatology Clin-
ical Trials Network. Assuming that topical corticosteroid 
alone results in 15% treatment success at 9 months,12 
clinicians were keen to see at least a 20% absolute differ-
ence between the groups if they were to justify the cost 
and complexity of introducing home-based NB-UVB as 
a potential new service in clinical practice (either on its 
own or in combination with topical corticosteroid).
The following sample size estimate formed the basis 
of the funding application and protocol at the start of 
the study: based on the assumption that 15% of partic-
ipants allocated to receive topical corticosteroid alone 
achieve treatment success,12 372 participants are required 
to detect an absolute difference of 20%, with 2.5% 
two-sided alpha and 90% power. Two comparisons are of 
coprimary interest, light therapy and light therapy plus 
topical corticosteroid each versus topical corticosteroid 
alone. Allowing for up to 15% non-collection of primary 
outcome data at 9 months, the target sample size was 440 
participants.
As data were limited to inform the sample size calcula-
tion for this trial, a planned sample size review by the Data 
Monitoring Committee was scheduled after 18 months 
of recruitment. This review was conducted in December 
2016 and resulted in a recommendation to increase 
the sample size by a further 76 participants in order to 
maintain 90% power to detect a risk difference of 20% 
between the topical corticosteroid arm and the other 
two arms. The final sample size estimate is therefore 516 
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participants. This recommendation was approved by the 
Trial Steering Committee and the funders.
Statistical methods
The primary approach to between-group comparisons 
will be to analyse participants according to the group 
to which they were allocated, regardless of treatment 
received, levels of adherence and with multiple imputa-
tion of missing outcome data.
Baseline data will be presented descriptively, and 
presented by intervention group.
For the primary outcome, number and percentage of 
participants achieving ‘treatment success’ will be reported 
for each treatment group at 9 months from randomi-
sation. Randomised groups will be compared using a 
generalised linear model for binary outcome adjusted by 
centre, body site of vitiligo and age. The primary effec-
tiveness parameter for the two coprimary comparisons of 
topical corticosteroid versus NB-UVB light, and topical 
corticosteroid versus NB-UVB light plus topical cortico-
steroid, will be the risk difference in the proportion of 
participants achieving treatment success at 9 months, 
along with 95% CI and exact P value. We will also report 
relative effects using risk ratios. Sensitivity analyses will 
be conducted to (i) further adjust for any variables with 
marked imbalance at baseline, (ii)repeat primary analysis 
based on participants whose primary outcome is available 
at 9 months and (iii) investigate the effects of treatment 
adherence. Planned subgroup analyses are (i) children 
versus adults and (ii) by body region of the target vitiligo 
patch. Further secondary analyses will be defined in the 
statistical analysis plan prior to locking the trial database. 
These analyses will be conducted by inclusion of appro-
priate interaction terms in the regression model, and will 
be considered as exploratory.
Analyses investigating other follow-up times, treatment 
success of patches on other body sites and other secondary 
outcomes will be analysed by a similar approach, using 
appropriate regression modelling depending on outcome 
type.
All analyses will be specified in a statistical analysis plan 
to be finalised and approved by the Data Monitoring 
Committee and Trial Steering Committee prior to locking 
the database.
Interim analyses
There are no planned interim between-group analyses.
health economic evaluation
An incremental cost analysis will be conducted from an 
NHS perspective capturing the intervention resource use 
and other health resource use throughout the treatment 
and follow-up period (21 months in total). In addition 
to an NHS perspective, but presented separately, an esti-
mate of out-of-pocket and time costs of treatment for 
participants and parents/guardians will be recorded. 
Intervention and wider healthcare costs will be estimated 
during the trial through participant dairies and case 
report forms (CRFs). Resource use will be valued using 
published unit costs or participant-reported estimates 
for a common price year. Both costs and benefits will be 
discounted using recommended rates.32
Both an incremental cost-effectiveness analysis using 
the trial primary outcome to estimate the incremental 
cost per successful treatment and cost-utility anal-
ysis estimating incremental cost per quality-adjusted 
life years (QALY) will be conducted. Utility will be 
measured at baseline, 9 months and 21 months using the 
EQ-5D-5L26–28 (for adults and children aged 11 years or 
over) and CHU-9D28–31 (for children aged 5–17 years) 
questionnaires, which will be used to estimate the QALY 
over the study period using linear interpolation and area 
under the curve analysis with and without baseline adjust-
ment.33 In the base case, separate cost utility analyses will 
be presented for those aged 18 years and over using the 
EQ-5D-5L to estimate QALYs and for those aged under 18 
years using the CHU-9D. Where appropriate (ie, in the 
absence of either intervention dominating), the incre-
mental cost-effectiveness of NB-UVB alone compared 
with TCS alone and separately of NB-UVB plus TCS 
compared with TCS alone will be estimated by dividing 
the difference in costs by the difference in QALYs. Deci-
sion uncertainty will be presented via Cost-Effectiveness 
Acceptability Curves based on non-parametric bootstrap-
ping of cost and effect pairs.34 35 This will provide robust 
trial evidence to inform decision makers about the likely 
cost-effectiveness of interventions for vitiligo in particular 
about whether NB-UVB light is more cost-effective than 
topical corticosteroid alone and about whether combina-
tion treatment offers greater value for money than TCS 
treatment alone.
Patient and public involvement
People with vitiligo have helped to prioritise this research 
question through a James Lind Alliance Priority Setting 
Partnership, which highlighted this as a priority topic.16 
A patient representative was a member of the Trial Devel-
opment Group, a coapplicant on the funding award and 
has contributed to the design and conduct of the trial 
throughout (including the external pilot RCT,15 and 
development of the training video (found at www. vitiligo-
study. org. uk).
Our choice of outcome measures was informed by feed-
back from people with vitiligo that suggested a disparity 
between what has previously been measured in vitiligo 
trials and what patients feel is important.21 They also 
contributed to the choice of outcome measures, through 
involvement in development of the core outcome set 
for vitiligo,22 and in development and validation of the 
primary outcome scale (VNS).23 36
Throughout the trial, people with vitiligo have contrib-
uted to the development of training materials and have 
commented on the suitability of participant-facing 
materials and questionnaires. They are continuing to 
contribute to awareness and engagement activities. The 
trial is supported by the UK Vitiligo Society and a patient 
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representative provides trial oversight as a member of the 
Trial Steering Committee. A panel consisting of three 
people with vitiligo will assess the digital images to provide 
blinded outcome assessment of the primary outcome.
Ethics and dissemination
Protocol amendments
The methods described in this protocol reflect the current 
protocol (V.5.0 dated 18 January 2018). A summary 
of protocol amendments that took place after start of 
recruitment are summarised in table 3.
Consent
Age-appropriate participant information sheets are 
provided for all trial participants, and ample opportunity 
is given to discuss the study with the study team before 
agreeing to take part. All participants will provide written 
informed consent (or assent in the case of children under 
16) for participation, retention and use of the trial data 
by members of the research group (use of the trial photo-
graphs for further research or trial reporting is optional).
Confidentiality
Trial data and individual participants’ medical informa-
tion obtained as a result of this study is considered confi-
dential. Participant confidentiality is ensured by using 
identification code numbers to correspond to treatment 
data in the computer files and on trial photographs.
Post-trial care
After completing the trial, participants will continue to 
receive normal vitiligo care in accordance with local prac-
tice. A summary of the trial results will be sent to partici-
pants if they have given consent for this.
Dissemination policy
Results will be reported in full through the National Insti-
tute for Health Research Journal series (open access), 
as well as through peer-reviewed journals, conferences, 
participant newsletters, patient focused charities and 
websites.
dIsCussIon
The HI-Light Vitiligo Trial is an appropriately powered, 
pragmatic, RCT that addresses a topic that has been 
identified as important by people with vitiligo, health-
care professionals who treat them and by the NIHR. It is 
unique in that it includes both children and adults with 
early and limited vitiligo, places particular emphasis on 
patient-reported outcomes and has been delivered with 
the support of a professional Clinical Trials Unit.
We support the development and use of core outcome 
sets in clinical trials and have included outcomes that 
are currently recommended as part of the core outcome 
set for vitiligo.22 However, outcomes research is rapidly 
evolving. Since starting the trial, further guidance has 
emerged37 suggesting that 80%, rather than 75% repig-
mentation, should be used to represent a meaningful 
treatment response, and that maintenance of repig-
mentation should be evaluated 6 months after stopping 
treatment. We will consider this updated guidance when 
finalising our statistical analysis plan and final write-up, to 
ensure that data are presented in a way that will facilitate 
comparison with other trial datasets in the future.
Alongside the trial, a mixed methods process evalu-
ation study is being conducted to explore barriers and 
facilitators to use of the trial interventions in normal 
care. The views of trial participants, healthcare profes-
sions and commissioners on the use of the trial inter-
ventions will be sought. A process evaluation can help to 
explain trial findings, explore how intervention delivery 
within the trial may differ from ‘real-world’ delivery and 
identify issues important to the transferability of an effec-
tive intervention outside the trial.38 This process evalua-
tion is particularly relevant for a study such as HI-Light, 
where hand-held NB-UVB devices represent a new way 
Table 3 Summary of protocol amendments that impacted on trial design
Protocol Date Summary of changes
2.0 11 March 2015 Added details of the MRC systematic techniques for  assisting recruitment to trials (START) 
substudy
3.0 30 Sepember 2015 Clarified inclusion and exclusion criteria; added more details about training participants to 
use trial treatments; procedures clarified for digital images outcome analyses; changes to 
adverse events (AE) handling for erythema (grade 1 and 2 are not AE, but expected reactions) 
and amendment of prespecified subgroup analysis to remove a comparison of active and 
inactive patches (as by definition all target patches will be active), and add a subgroup analysis 
evaluating response of target patch by region of the body.
4.0 03 March 2017 Added details of the nested process evaluation; updates to the safety handling section; 
introduction of an online automated the blind brake procedure; change to sample size following 
sample size review by the Data Monitoring Committee (DMC).
 5.0  18 January 2018 Due to trial timelines some participants will not receive the full 12 month follow-up but will 
receive quality of life questionnaires and study feedback questions; Updates to statistical 
analyses section to reflect the statistical analysis plan; addition of output testing of NV-UVB 
devices after end of treatment phase. 
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of delivering care with complexity around training and 
treatment adherence.
Several resources have been developed during the set-up 
of this trial that may be helpful for other researchers 
wishing to conduct trials of home light therapy, or for 
health providers wishing to implement the study findings. A 
training video demonstrating how to use home NB-UVB is 
freely available, along with training materials for conducting 
MED tests and copies of study documents and treatment 
diaries (www. vitiligostudy. org. uk). The trial is also contrib-
uting to a nested methodological study (START) looking 
at the value of interactive websites to facilitate recruitment 
and retention in trials (http:// research. bmh. manchester. 
ac. uk/ mrcstart). Results of the process evaluation and 
START study will be reported separately.
trial status
The HI-Light Vitiligo Trial is ongoing. The first participant 
was randomised into the trial in July 2015 and recruitment 
is anticipated to be completed by Quarter 4 2017.
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